Publications by Lan Wang - ePrints - Newcastle University

Browsing publications by Lan Wang.

Newcastle Authors	Title	Year
Dr Nicola Johnson Dr Johanne Bentley Lan Wang Professor Craig Robson Professor Nicola Curtin et al.	Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells (British Journal of Cancer, (2010), 102, 2, (342-350), 10.1038/sj.bjc.6605479)	2024
Dr Hannah Stewart Dr Mathew Martin Lan Wang Dr Eilidh Mackenzie Professor Mike Waring et al.	Conformational study into alkyl-aryl ureas to inform drug discovery	2023
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Lan Wang Professor Nilanjan Chakraborty	Effects of the cold wall boundary on the flame structure and flame speed in premixed turbulent combustion	2021
Daniel Wood Svitlana Korolchuk Dr Natalie Tatum Lan Wang Professor Jane Endicott et al.	Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition	2019
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Dr Christopher Wong Dr Ian Hardcastle Christopher Matheson Professor Herbie Newell Dr Mangaleswaran Sivaprakasam et al.	Structure-guided design of purine-based probes for selective Nek2 inhibition	2017
Dr Gary Beale Dr Emma Haagensen Huw Thomas Lan Wang Charlotte Revill et al.	Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer	2016
Lan Wang Professor Herbie Newell Professor Steve Wedge	Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation	2016
Dr Benoit Carbain Dr Allyson Campbell Dr Celine Cano Professor Jane Endicott Emeritus Professor Bernard Golding et al.	8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode	2014
Honorine Lebraud Emeritus Professor Bernard Golding Elisa Meschini Dr Celine Cano Lan Wang et al.	Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors	2014
Dr Mathew Martin Elisa Meschini Lan Wang Dr Regina Mora Vidal Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2014
Dr Benoit Carbain Christopher Coxon Honorine Lebraud Christopher Matheson David Turner et al.	2-arylamino-6-ethynylpurines as Potent Irreversible Inhibitors of the Mitotic Kinase Nek2	2012
Dr Sonja Baumli Dr Alison Hole Lan Wang Professor Martin Noble Professor Jane Endicott et al.	The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b	2012
Elisa Meschini Professor Jane Endicott Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Herbie Newell et al.	Design and synthesis of dual CDK2 and CDK7 inhibitors	2010
Dr Nicola Johnson Dr Johanne Bentley Lan Wang Professor Herbie Newell Professor Craig Robson et al.	Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells	2010
Dr Francesco Marchetti Dr Celine Cano Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Synthesis and biological evaluation of 5-substituted O⁴-alkylpyrimidines as CDK2 inhibitors	2010
Dr Christopher Wong Professor Roger Griffin Dr Ian Hardcastle Dr Julian Scott Northen Lan Wang et al.	Synthesis of sulfonamide-based kinase inhibitors from sulfonates by exploiting the abrogated S_N2 reactivity of 2,2,2-trifluoroethoxysulfonates	2010
Huw Thomas Dr Kappusamy Saravanan Lan Wang Mei Lin Dr Julian Scott Northen et al.	Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity	2009
Professor Herbie Newell Huw Thomas Lan Wang Dr Celine Roche Dr Ian Hardcastle et al.	[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU6301	2008
Lan Wang Professor Nicola Curtin Professor Herbie Newell	Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked	2008
Huw Thomas Dr Christopher Calabrese Michael Batey Suzanne Kyle Professor Herbie Newell et al.	Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial	2007
Dr Francesco Marchetti Kerry Louise Sayle Dr Johanne Bentley Professor William Clegg Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2	2007
Huw Thomas Dr Christopher Calabrese Professor Herbie Newell Lan Wang Professor Nicola Curtin et al.	Identification of a PARP inhibitor for clinical trial: Preclinical studies	2006
Professor Roger Griffin Andrew Henderson Professor Nicola Curtin Professor Jane Endicott Dr Ian Hardcastle et al.	Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination	2006
Professor Herbie Newell Professor Roger Griffin Richard Davison Lan Wang Professor Nicola Curtin et al.	Effect of cell cycle inhibition on cisplatin-induced cytotoxicity	2005
Professor Roger Griffin Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Dr Ian Hardcastle et al.	Potent CDK2 inhibitors generated using a variant of the cope elimination	2005
Dr Allyson Campbell Dr YuZhu Cheng Lan Wang Professor Nicola Curtin Emeritus Professor Bernard Golding et al.	Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation	2005
Andrew Henderson Dr YuZhu Cheng Professor Nicola Curtin Emeritus Professor Bernard Golding Professor Roger Griffin et al.	Searching for potent CDK2 inhibitors using a variant of the Cope elimination	2005
Dr Christopher Calabrese Michael Batey Professor Alan Calvert Professor barbara Durkacz Suzanne Kyle et al.	Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361	2004
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase	2004
Dr Ian Hardcastle Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al.	N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2	2004
Professor Nicola Curtin Lan Wang Suzanne Kyle Dr Christine Arris Professor barbara Durkacz et al.	Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells	2004
Dr Veronique Mesguiche Rachel Parsons Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin et al.	4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2	2003
Dr Christopher Calabrese Michael Batey Huw Thomas Professor barbara Durkacz Lan Wang et al.	Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies	2003
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al.	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2	2003
Dr Christopher Calabrese Professor Nicola Curtin Suzanne Kyle Huw Thomas Lan Wang et al.	Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure	2002
Dr Johanne Bentley Dr Christine Arris Professor Nicola Curtin Professor Jane Endicott Dr Ashleigh Gibson et al.	Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor	2002
Professor Nicola Curtin Dr Stephen Barton Michael Batey Dr Christopher Calabrese Professor Alan Calvert et al.	Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.	2001
Lan Wang Professor Nicola Curtin Professor Herbie Newell	Tumor radiosensitization using TBI-361, an inhibitor of poly (ADP-ribose) polymerase (PARP)	2001
Lan Wang Suzanne Kyle Alex White Professor Alan Calvert Professor Nicola Curtin et al.	Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines	2000
Professor Nicola Curtin Suzanne Kyle Lan Wang Professor barbara Durkacz Professor Roger Griffin et al.	Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors	1999